Verily Life Sciences, the medical arm of Google parent Alphabet (NSDQ:GOOGL), said today Singapore-based investment company Temasek invested $800 million as part of a partnership deal.
As part of the deal, Temasek will gain a minority stake in the company. The majority of the investment will be funded in the coming days, while the remainder of the investment is scheduled for the 2nd half of 2017.
“Temasek has a history of thoughtful and enduring capital investments, including in life sciences and healthcare, and this commitment to a long-term collaboration with Verily is a meaningful affirmation of our strategy. With a substantial network and insights into the economies in Asia, Temasek will provide valuable guidance as we look to ex-US markets with our development partners,” Verily CEO Andrew Conrad said in a press release.
As part of the investment and partnership, Temasek will nominate a director to Verily’s board.
Last month, Nikon (TYO:7731) subsidiary Optos and Verily inked a deal to develop technologies for machine learning-enabled retinal imaging.
The deal calls for the companies will collaborate on improving the screening for diabetic retinopathy and diabetic macular edema, both among the leading causes of blindness worldwide.
The post Temasek invests $800m, inks partnership deal with Verily appeared first on MassDevice.
from MassDevice http://ift.tt/2jBNkhw
Cap comentari:
Publica un comentari a l'entrada